Sutimlimab
 | This article relies largely or entirely on a single source. (October 2018) |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric/humanized hybrid |
| Target | complement component 1s |
| Clinical data | |
| Other names | BIVV009 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Sutimlimab (INN;[1] development code BIVV009) is a monoclonal antibody that is being investigated for cold agglutinin disease.
This drug is being developed by Bioverativ, a Sanofi Company. As of 2018[update], sutimlimab is undergoing Phase III trials.
Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro. ([2])
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
- ^ Nikitin PA (2019). "C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro". Journal of Immunology. 202 (4): 1200–1209. doi:10.4049/jimmunol.1800998. PMC 6360260. PMID 30635392.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |